ImprimisRx to Focus on Investments in Quality at the 2019 AAO Meeting

Source: ImprimisRx

ImprimisRx announced its participation at the upcoming 2019 American Academy of Ophthalmology (AAO) annual meeting to be held in San Francisco, October 12-15.

As part of ImprimisRx’s commitment to quality manufacturing, the company will be discussing its ongoing investments in cGMP (Current Good Manufacturing Practices). cGMP standards (21 C.F.R. Parts 210 and 211) are the highest federal drug manufacturing standards. As an FDA-registered and FDA-inspected outsourcing facility, ImprimisRx has made and continues to make significant investments in equipment, processes and personnel to comply with these standards. ImprimisRx’s cGMP compliance program is designed to ensure ImprimisRx’s status as the leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business in the United States. 

“The need for our formulations has never been greater. With nearly 3.5 million sterile doses dispensed to date and over 6,000 ophthalmic healthcare professionals prescribing our formulations, we see demand continuing to grow as we expand our unique suite of offerings,” John Saharek, President of ImprimisRx, said in a company news release. “This year has been a record-breaker and 2020 is likely going be another year of record-breaking growth. Producing products at the highest federal quality standards in our facilities, which are all inspected by the US Food and Drug Administration (FDA), is what our customers expect; and it is what they will get as we ensure access to affordable medications for individuals with needs not adequately met by FDA-approved products.”

At the conference, attendees will have the opportunity to meet with ImprimisRx representatives at Exhibit #7601 in the Moscone Center West Hall to learn about ImprimisRx’s full portfolio of formulations, including several new topical and injectable formulations to further expand the ImprimisRx portfolio of ophthalmic-focused, acute care compounded medications which help address unique patient needs.  


Related Content